Cubist Systematic Strategies LLC lowered its holdings in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) by 21.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 74,220 shares of the company's stock after selling 20,335 shares during the quarter. Cubist Systematic Strategies LLC owned 0.12% of Kezar Life Sciences worth $639,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Great West Life Assurance Co. Can bought a new stake in Kezar Life Sciences during the 3rd quarter valued at about $26,000. Tower Research Capital LLC TRC raised its position in Kezar Life Sciences by 88.9% during the 3rd quarter. Tower Research Capital LLC TRC now owns 6,777 shares of the company's stock valued at $58,000 after purchasing an additional 3,190 shares in the last quarter. Robeco Institutional Asset Management B.V. bought a new position in shares of Kezar Life Sciences during the 3rd quarter worth $68,000. ProShare Advisors LLC bought a new stake in shares of Kezar Life Sciences in the third quarter valued at about $100,000. Finally, Virtu Financial LLC purchased a new position in Kezar Life Sciences during the 3rd quarter valued at about $104,000. Institutional investors own 84.03% of the company's stock.

Kezar Life Sciences Price Performance

Shares of NASDAQ KZR opened at $4.64 on Friday. The company has a market cap of $317.28 million, a PE ratio of -4.59 and a beta of 0.25. The company has a debt-to-equity ratio of 0.03, a quick ratio of 31.15 and a current ratio of 31.15. The business has a 50-day simple moving average of $6.46 and a two-hundred day simple moving average of $7.45. Kezar Life Sciences, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $18.55.

Insider Activity at Kezar Life Sciences

In related news, major shareholder Morningside Venture Investment sold 25,000 shares of the company's stock in a transaction that occurred on Friday, February 3rd. The stock was sold at an average price of $7.15, for a total value of $178,750.00. Following the sale, the insider now owns 5,487,993 shares in the company, valued at $39,239,149.95. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 248,276 shares of company stock valued at $1,708,683 in the last ninety days. Company insiders own 7.80% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wells Fargo & Company lowered their target price on Kezar Life Sciences from $17.00 to $14.00 and set an "overweight" rating for the company in a report on Tuesday, January 3rd.

Kezar Life Sciences Company Profile

(Get Rating)

Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.

Read More

• Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
• What the SVB Financial Collapse Means for U.S. Banks
• MarketBeat Week in Review – 3/6 – 3/10
• 2 Offshore Drilling Stocks Set to Extract Big Profits
• Three Staples Stocks With Double-Digit Upside Ahead
• Can Investors Trust Consumers to Lift American Outdoor Brands?

Want to see what other hedge funds are holding KZR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating).

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.